Basic Registry Information

- **16** Registry Sites
- **3,075** Participants
- **10,813** Clinic Visits
- **11** Years of Data

Demographics

- **78.8%** Female
- **88.4%** White
- **4.3%** Hispanic
- **64.6** Average Age

Clinical Characteristics and Comorbidities

- **84.9%** diagnosed with bronchiectasis
- **63.8%** have a history of pneumonia
- **53.4%** diagnosed with past or current NTM*
- **21.0%** diagnosed with past or current pseudomonas**
- **18.3%** COPD
- **26.3%** Asthma
- **43.3%** GERD***

* Defined by one or more positive culture -or- by physician diagnosis
** Defined by one or more positive culture
*** GERD=Gastroesophageal Reflux Disease
* One site in Illinois is no longer an active Registry site
** Site in Arizona is no longer an active Registry site
*** Represents participation in District of Columbia

**Cigarette Smoking**

- 58.5% NON-SMOKERS
- 39.3% FORMER SMOKERS

**Lung Function**

- **Pre-Bronchodilator**
  - Average FEV1 was 1.9 (±0.7) Liters & FEV1% Predicted was 72.8 (±22.3)
  - Average FVC was 2.7 (±0.9) Liters & FVC% Predicted was 82.0 (±20.2)

- **Post-Bronchodilator**
  - Average FEV1 was 1.9 (±0.7) Liters & FEV1% Predicted was 74.5 (±22.7)
  - Average FVC was 2.8 (±0.9) Liters & FVC% Predicted was 82.8 (±20.8)

**Respiratory Symptoms**

- Cough: 73.2%
- Fatigue: 43.1%
- Wheezing: 27.7%
- Hemoptysis: 20.2%
Exacerbations

59.2% experienced at least one exacerbation of bronchiectasis within 2 years prior to enrolling in the Registry. Over 35% experienced two or more exacerbations during that 2-year period.

Hospitalizations

20.6% were hospitalized for pulmonary illness at least once within the 2 years prior to enrolling in the Registry. Over 7% were hospitalized for pulmonary illness two or more times during that 2-year period.

Bronchial Hygiene & Treatment

52.5% have used bronchial hygiene measures
72.5% treated with oral antibiotics
13.1% treated with home IV antibiotics
12.4% treated with inhaled antibiotics

About the Bronchiectasis and NTM Research Registry

The Bronchiectasis and NTM Research Registry is a program of the COPD Foundation’s Bronchiectasis and NTM Initiative. The Registry is a consolidated database of non-Cystic Fibrosis (non-CF) Bronchiectasis and/or NTM patients from multiple clinical institutions across the United States. Once enrolled in the Registry, data on participants is collected annually. The goal of the Registry is to support collaborative research and assist in the planning of multi-center clinical trials for the treatment of non-CF Bronchiectasis and/or NTM lung disease.

About the Bronchiectasis and NTM Initiative

The Bronchiectasis and NTM Initiative aims at meeting the unmet needs of the Bronchiectasis and NTM communities. The Initiative offers a global online platform for community members to connect and interact (BronchandNTM360social), educational resources for patients, and research programs meant to assist in accelerating therapeutic solutions and cures for both, Bronchiectasis and NTM. The COPD Foundation works collaboratively with NTM Info & Research on projects of the Bronchiectasis and NTM Initiative.

To learn more about the programs of the Bronchiectasis and NTM Initiative, please visit www.BronchiectasisandNTMInitiative.org or contact Delia Prieto at dprieto@copdfoundation.org.

*The data in this document is based on available baseline Registry data as of January 2019.*
<table>
<thead>
<tr>
<th>Institution</th>
<th>Contacts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mayo Clinic Rochester</td>
<td>Timothy R. Aksamit, M.D.</td>
</tr>
<tr>
<td>Columbia University Medical Center/ NY Presbyterian Hospital</td>
<td>Byron Thomashow, M.D. Angela DiMango, M.D.</td>
</tr>
<tr>
<td>Mount Sinai St. Luke’s and Mount Sinai Roosevelt</td>
<td>Edward Eden, M.D.</td>
</tr>
<tr>
<td>Georgetown University Hospital</td>
<td>Anne O’Donnell, M.D.</td>
</tr>
<tr>
<td>Mayo Clinic Jacksonville</td>
<td>Margaret Johnson, M.D.</td>
</tr>
<tr>
<td>National Institute of Allergy and Infectious Diseases</td>
<td>Kenneth Olivier, M.D.</td>
</tr>
<tr>
<td>National Jewish Health</td>
<td>Charles Daley, M.D.</td>
</tr>
<tr>
<td>New York University</td>
<td>Doreen Addrizzo-Harris, M.D.</td>
</tr>
<tr>
<td>Oregon Health and Science University</td>
<td>Alan Barker, M.D.</td>
</tr>
<tr>
<td>University of Chicago</td>
<td>Pamela J. McShane, M.D.</td>
</tr>
<tr>
<td>University of Connecticut</td>
<td>Mark Metersky, M.D.</td>
</tr>
<tr>
<td>University of Miami</td>
<td>Matthias Salathe M.D.</td>
</tr>
<tr>
<td>University of North Carolina at Chapel Hill School of Medicine</td>
<td>Michael Knowles, M.D. Leigh Anne Daniels, M.D. Peadar Noone, M.D.</td>
</tr>
<tr>
<td>University of Pennsylvania</td>
<td>Gregory Tino, M.D.</td>
</tr>
<tr>
<td>University of Texas Health Science Center</td>
<td>David Griffith, M.D.</td>
</tr>
<tr>
<td>San Antonio Veterans Administration*</td>
<td>Diego Maselli, M.D.</td>
</tr>
</tbody>
</table>

*Pending contract execution